Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rang in Aktien #29900
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Aktienkurs
$1.10
Zuletzt synchronisiert: 2023-06-07
Marktkapitalisierung
$19.12M
Veränderung (1 Tag)
-0.90%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Satsuma Pharmaceuticals, Inc. (STSA)

Kategorie

Dividendenrendite-Verlauf für Satsuma Pharmaceuticals, Inc. (STSA)
Dividendenrendite (TTM) von Satsuma Pharmaceuticals, Inc. (Aktienkürzel: STSA) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Satsuma Pharmaceuticals, Inc. (STSA) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber